Cystic Fibrosis Therapeutics Market Size to Attain USD 39.15 Billion at 14.24% CAGR by 2034

The global cystic fibrosis therapeutics market size is calculated at USD 11.81 billion in 2025 and is expected to reach around USD 39.15 billion by 2034, growing at a CAGR of 14.24% for the forecasted period.

Ottawa, Sept. 26, 2025 (GLOBE NEWSWIRE) -- The global cystic fibrosis therapeutics market size was valued at USD 10.34 billion in 2024 and is predicted to hit around USD 39.15 billion by 2034, rising at a 14.24% CAGR, a study published by Towards Healthcare a sister firm of Precedence Research.

This market is rising due to breakthroughs in CFTR modulator therapies, improved early diagnosis, expanding patient access, and increased R&D into adjunctive treatments are collectively driving demand and revenue in the cystic fibrosis therapeutics market.

The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/5421

Key Takeaways:

• North America held the major share of the market in 2024.
• Asia-Pacific is anticipated to grow at the fastest rate in the market during the forecast period.
• By drug class, the CFTR modulators segment held a dominant presence in the market in 2024.
• By drug class, the pancreatic enzyme supplements segment is anticipated to grow with the highest CAGR in the market during the studied years.
• By route of administration, the oral segment held the largest share of the market in 2024.
• By route of administration, the inhaled segment is projected to expand rapidly in the market in the coming years.
• By distribution channel, the hospital pharmacies segment led the global market in 2024.
• By distribution channel, the online pharmacies segment is expected to grow at the fastest rate in the market during the forecast period.

Market Overview:

Can cystic fibrosis be treated and why is the cystic fibrosis market surging growth?

Cystic fibrosis does not currently have a cure, but it is a treatable condition that can be managed with therapies to control symptoms, improve quality of life, and slow disease progression. Cystic fibrosis is a life-limiting genetic condition characterized by the build-up of thick mucus in the lungs, pancreas, and other organs, which leads to complications in respiratory, gastrointestinal, and nutritional system functioning.

The worldwide therapeutics market for cystic fibrosis is expanding quickly, worth tens of billions of dollars and expected to nearly double in the next 5-10 years. Rapid growth of the cystic fibrosis therapeutics market will continue to be driven by increasing cystic fibrosis diagnostic rates, favourable health policies, and heightened advocacy efforts to raise awareness.

As the cystic fibrosis treatment goals shift from merely managing symptoms to addressing underlying causes, the cystic fibrosis therapeutics industry becomes increasingly focused on precision medicine, therapies based on genotype, and completely new delivery pathways, and is pushing standards of care in new directions.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Major Growth Drivers:

CFTR modulators, drugs designed to correct, potentiate, or restore the action of the defective chloride ion channel is likely the most significant driver of the market growth. They change the underlying pathophysiology of cystic fibrosis rather than treating symptoms only, which has resulted in market share and premium pricing. Improved diagnosis, particularly newborn screening, larger genetic panels, and improved awareness based on newly identified rarer populations with cystic fibrosis diagnoses, is also a driver of market growth, which also expands the eligible people or population for newer therapy options.

Regulatory and policy support will lower barriers and increase the pipeline entry of new therapies. Finally, adjunct therapies and improvement in delivery devices will further impact quality of life and adherence. Taken together, these drivers provide the foundation for your positive CAGR forecasts.

Key Drifts:

Significant Trends Shaping Cystic Fibrosis Treatments:

• Expansion of genotypes and next-generation modulators: The approval of medications such as for use in additional CFTR mutations beyond the traditionally targeted F508del means there will be an expansion in eligible populations.
• Expansion in early intervention: Clinical approvals to begin treating children in younger and younger age groups are becoming common practice in order to intervene earlier, before irreversible organ damage occurs.
• Increasing interest in inhaled and non-oral modalities: Inhaled delivery and non-oral route of administration for therapies designed to target the lung are quickly gaining traction as it provides improved efficacy, especially surrounding the areas of mucolytics, inhaled antibiotics, and new biologics.
• Improvement in patient access in the Asia-Pacific region: As healthcare systems improve, awareness is raised, and favorable regulatory environments are established, Asia-Pacific is quickly emerging as the fastest growing regional market. Under-diagnosis is now being addressed, and patient registries are being set up.

Become a valued research partner with us - https://www.towardshealthcare.com/schedule-meeting

Significant Challenge:

• A significant and persistent issue is the exorbitant cost of expensive CF therapies, especially the newer CFTR modulators.
• These prices are often in the hundreds of thousands of US dollars annually for triple-combination therapies, which severely restricts access for people in low or middle-income countries, or regions with limited reimbursement.
• Related to this is the mutational heterogeneity of CFTR gene defects. Not everyone benefits from the same modulator, while some mutations are non-responsive to whatever therapies are available, resulting in further gaps in both caregiver and coverage.
• Further complications to scalability and affordability of CF therapeutics are regulatory delays, patent expiries, manufacturing issues and supply chain problems.

Regional Analysis:

North America is the largest market for Cystic fibrosis. This is due to sophisticated healthcare infrastructure, strong reimbursement systems, a high prevalence of diagnosed cases, rapid adoption of new modalities, and large amounts of R&D investment. Major pharmaceutical companies are based there, and their regulatory systems support this prominence through expedited regulatory approval, while also permitting premium pricing.

The Asia-Pacific region can be expected to grow the fastest, as it benefits and develops increased awareness surrounding CF, more investment in healthcare in general, better diagnostic capacity, and expanded clinical trials in ongoing and developing therapies, as well as improving policies related to rare diseases in general. Countries in the region are beginning to add CF.

Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership

Segmental Insights:

By Drug Class:

The CFTR modulator segment the dominant segment and revenue-generating therapy class, especially with all CFTR modulator drugs among the leading therapies. These therapies treat the underlying defect in CF, rather than the symptoms, which leads to overall better growth potential when compared to other classes.

Pancreatic enzyme supplements segment is expected to see one of the highest CAGRs across forecast timelines. These supplements play a very important role in treating dietary complications and the malabsorption issues often experienced by CF patients, which has only been bolstered through advancements in new formulations and access for more patients.

By Route of Administration:

The oral segment dominates the cystic fibrosis market. The majority of CFTR modulators and pancreatic enzyme supplements are administered orally, which is more convenient, leads to better adherence, and is important for long-term treatment. Many of the older therapies and those that are among the most widely used are oral therapies.

The inhaled route of administration is increasing rapidly, with inhaled antibiotics, various mucolytics, and inhaled biologics adding new therapies that are increasing rapidly in clinical use and implementation. They offer direct delivery to lung tissue, potentially reducing systemic side-effects and improving efficacy in pulmonary symptoms.

By Distribution Channel:

Hospital pharmacies segment dominates the market as these therapies are provided to patients through this channel, they remain an important distribution channel for most initial prescriptions, severe exacerbations, IV antibiotics, or when monitoring of patients is needed. Hospital pharmacies are also closely connected to CF centers.

The online pharmacy is the fastest growing segment. Convenience to the patient for chronic therapy, cost comparison, and home delivery service are driving this expansion especially. Increased acceptance of telemedicine, digital health platforms, and continued improvement to logistics have supported the increased use of online distribution.

Browse More Insights of Towards Healthcare:

• The global GLP-1 drugs market size began at US$ 48.3 billion in 2024 and is forecast to rise to US$ 52.95 billion by 2025. By the end of 2034, it is expected to surpass US$ 121.13 billion, growing steadily at a CAGR of 9.63%.
• The global pain management drugs market size is calculated at USD 84.1 billion in 2024, grew to USD 87.58 billion in 2025, and is projected to reach around USD 126.17 billion by 2034. The market is expanding at a CAGR of 4.14% between 2025 and 2034.
• The anti-seizure medication market is rapidly advancing on a global scale, with expectations of accumulating hundreds of millions in revenue between 2025 and 2034.
• The global analgesics market size is calculated at USD 43.8 billion in 2024, grew to USD 46.53 billion in 2025, and is projected to reach around USD 80.26 billion by 2034. The market is expanding at a CAGR of 6.24% between 2025 and 2034.
• The global electron brachytherapy market size is calculated at US$ 451.36 million in 2024, grew to US$ 494.33 million in 2025, and is projected to reach around US$ 1121.66 million by 2034. The market is expanding at a CAGR of 9.52% between 2025 and 2034.
• The global minimally invasive surgery market size is calculated at US$ 81.69 billion in 2024, grew to US$ 94.8 billion in 2025, and is projected to reach around US$ 362.43 billion by 2034. The market is expanding at a CAGR of 16.05% between 2025 and 2034.
• The global brachytherapy market size recorded US$ 1.04 billion in 2024, set to grow to US$ 1.12 billion in 2025 and projected to hit nearly US$ 2.10 billion by 2034, with a CAGR of 7.27% throughout the forecast timeline.
• The global intravenous immunoglobulin market size is calculated at USD 17.12 billion in 2024, grew to USD 18.68 billion in 2025, and is projected to reach around USD 40.78 billion by 2034. The market is expanding at a CAGR of 9.14% between 2025 and 2034.
• The global viral sensitizers market size is calculated at USD 2.04 in 2024, grew to USD 2.34 billion in 2025, and is projected to reach around USD 8.02 billion by 2034. The market is expanding at a CAGR of 14.63% between 2025 and 2034.
• The global controlled substance market size marked US$ 93.7 billion in 2024 and is forecast to experience consistent growth, reaching US$ 98.71 billion in 2025 and US$ 157.7 billion by 2034 at a CAGR of 5.35%.

Recent Developments:

On July 1, 2025, the European Union granted approval for Alyftrek, marking an extension of access for patients aged six years and above with at least one F508del or other responsive CFTR mutation. This regulatory step reinforces market dominance for the therapy and helps address concerns of patent expiration on earlier modulators.

Cystic Fibrosis Therapeutics Market Key Players List

• AbbVie, Inc.
• Advanz Pharma Corp Ltd.
• Carbon Sciences
• Enterprise Therapeutics Ltd.
• Gilead Sciences
• Glox Therapeutics
• Novartis AG
• ReCode Therapeutics
• Rostra Therapeutics
• Sionna Therapeutics
• Trevi Therapeutics, Inc.
• Vertex Pharma Pharmaceuticals

Segments Covered in the Report

By Drug Class

• CFTR Modulators
• Pancreatic Enzyme Supplements
• Mucolytics
• Bronchodilators

By Route of Administration

• Oral
• Inhaled

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
  

By Region

• North America
  • US
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
    

Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/price/5421

Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

Access the Dashboard: https://www.towardshealthcare.com/access-dashboard

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Europe Region: +44 778 256 0738

North America Region: +1 8044 4193 44

APAC Region: +91 9356 9282 04

Web: https://www.towardshealthcare.com

Our Trusted Data Partners

Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest